A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL
Authors
Keywords
-
Journal
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-08-06
DOI
10.1002/hon.2662
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas
- (2017) Chengfeng Bi et al. HAEMATOLOGICA
- Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas
- (2017) Chengfeng Bi et al. HAEMATOLOGICA
- Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma
- (2016) Scott A. Ezell et al. Oncotarget
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
- (2015) E Van Den Neste et al. BONE MARROW TRANSPLANTATION
- First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
- (2015) B. Basu et al. CLINICAL CANCER RESEARCH
- Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies
- (2014) Toby A. Eyre et al. BRITISH JOURNAL OF HAEMATOLOGY
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
- (2013) Kurt G. Pike et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
- (2013) Li Dong et al. Journal of Hematology & Oncology
- Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
- (2012) J. A. Barnes et al. HAEMATOLOGICA
- Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
- (2011) M. Gupta et al. BLOOD
- Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium
- (2010) Sonali M. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- [18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy
- (2009) Wen Wee Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started